肾去神经术可降低难治性高血压患者MASLD及心肾代谢疾病风险
本研究采用目标试验模拟,利用TriNetX全球联邦健康研究网络数据,比较肾去神经术联合药物治疗与强化药物降压治疗对心肾代谢疾病风险的影响。倾向评分匹配后每组1735例患者,结果显示肾去神经术与MASLD、2型糖尿病、慢性肾脏病及主要不良心血管事件风险显著降低相关。研究支持自主神经功能障碍参与心肾代谢综合征进展。
要点
- 肾去神经术与MASLD风险降低相关,HR 0.38(95%CI 0.29-0.51)。
- 肾去神经术与2型糖尿病风险降低相关,HR 0.21(95%CI 0.13-0.33)。
- 肾去神经术与MACE风险降低相关,HR 0.46(95%CI 0.34-0.62)。
核心结论
- 难治性高血压患者接受肾去神经术控制交感神经系统,与CKM综合征(含MASLD、T2D、CVD、CKD)发生风险降低相关。
研究设计与样本
- 采用目标试验模拟设计,数据来源于TriNetX全球联邦健康研究网络。
- 治疗组为接受肾去神经术联合药物治疗的成人高血压患者,对照组为接受强化药物降压治疗(β受体阻滞剂、钙通道阻滞剂、ACEI、ARB、α受体阻滞剂或利尿剂中四类)的患者。
- 经1:1倾向评分匹配后每组1735例,基线特征均衡(平均年龄42岁 vs 41岁,SMD 0.05;男性52.6% vs 54.3%,SMD 0.03)。
主要发现
- 肾去神经术与MASLD风险降低相关,HR 0.38(95%CI 0.29-0.51)。
- 肾去神经术与T2D风险降低相关,HR 0.21(95%CI 0.13-0.33)。
- 肾去神经术与CKD风险降低相关,HR 0.26(95%CI 0.20-0.35)。
- 肾去神经术与MACE风险降低相关,HR 0.46(95%CI 0.34-0.62)。
- 肾去神经术与缺血性心脏病(HR 0.56,95%CI 0.39-0.80)、脑血管意外(HR 0.33,95%CI 0.20-0.52)及心力衰竭(HR 0.39,95%CI 0.25-0.62)风险降低相关。
关键数值与推荐
- 主要结局为MASLD/代谢相关脂肪性肝炎,次要结局包括T2D、CKD及MACE复合终点(心源性猝死、缺血性心脏病、脑血管意外、外周血管疾病、心力衰竭)。
- 高血压诊断依据ICD-10编码I10确定。
- 肾去神经术通过ICD-10或CPT编码识别,对照组定义为接受β受体阻滞剂、钙通道阻滞剂、ACEI、ARB、α受体阻滞剂或利尿剂中四类药物的强化降压方案。
临床怎么用
- 对于难治性高血压患者,肾去神经术可能带来超越降压作用的心肾代谢获益。
- 临床评估自主神经功能障碍相关心肾代谢风险时,可考虑肾去神经术作为综合干预手段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Introduction Autonomic dysfunction increases the risk of cardio-kidney-metabolic (CKM) syndrome including metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD). Renal denervation reduces renal sympathetic nerve activity and lowers blood pressure independent of long-term pharmacotherapy, with potential downstream effects on metabolic and hepatic pathways. We aimed to evaluate the impact of renal denervation, compared with intensive antihypertensive therapy, on cardiometabolic disease risk. Methods We conducted a target trial emulation using the TriNetX global federated health research network. Eligible participants were adults with hypertension (ICD-10 code I10) who were treated with either renal denervation therapy and pharmacological treatment (identified via ICD-10 or Current Procedural Terminology codes), acting as the treatment group, or an intensive pharmacological antihypertensive regime (four of a beta blocker, calcium channel blocker, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, alpha blocker or diuretic), acting as the control group. Propensity score matching (1:1) balanced the treatment and control groups, accounting for confounding variables. The primary outcome was of MASLD/metabolic dysfunction-associated steatohepatitis (MASH), while secondary outcomes included T2D, CKD and a composite of major adverse cardiovascular events (MACE): sudden cardiac death, ischaemic heart disease (IHD), cerebrovascular accident (CVA), peripheral vascular disease (PVD) and heart failure (HF). Cox regression generated hazard ratios (HRs) and 95% confidence intervals (CIs). Results After matching, 1735 patients remained in each group, with well-balanced baseline characteristics (mean age 42 vs. 41 years; standardised mean difference [SMD] 0.05; 52.6% vs. 54.3% male; SMD 0.03). After PSM, renal denervation was associated with a lower risk of MASLD (HR 0.38 [0.29, 0.51]), T2D (HR 0.21 [0.13, 0.33]), CKD (HR 0.26 [0.20, 0.35]), MACE (HR 0.46 [0.34, 0.62]), IHD (HR 0.56 [0.39, 0.80]), CVA (HR 0.33 [0.20, 0.52]) and HF (HR 0.39 [0.25, 0.62]). Conclusion Control of the sympathetic nervous system with renal denervation therapy in patients with resistant hypertension is associated with a lower risk of incident CKM syndrome including MASLD, T2D, CVD and CKD, supporting the role of autonomic dysfunction in the progression of cardiometabolic d
引用
- Diabetes, Obesity and Metabolism:Reduced Risk of MASLD and Cardiometabolic Disease Following Renal Denervation Therapy in Patients With Resistant Hypertension
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。